Quick Answer
Matinas BioPharma Holdings, Inc. reported Operating Income Loss of -$6.96 million for the year ending 2025.
- Matinas BioPharma Holdings, Inc. showed an increase of +71.7% in Operating Income Loss from 2024 to 2025.
- This data is from Matinas BioPharma Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$2.13 million | Q2 2014: -$2.42 million | Q3 2014: -$2.61 million | Q1 2015: -$2.57 million | Q2 2015: -$2.40 million | Q3 2015: -$2.16 million | Q1 2016: -$2.24 million | Q2 2016: -$1.62 million | Q3 2016: -$1.84 million | Q1 2017: -$4.49 million | Q2 2017: -$3.98 million | Q3 2017: -$3.41 million | Q1 2018: -$4.12 million | Q2 2018: -$3.40 million | Q3 2018: -$2.95 million | Q1 2019: -$4.10 million | Q2 2019: -$4.52 million | Q3 2019: -$4.56 million | Q1 2020: -$6.35 million | Q2 2020: -$5.77 million | Q3 2020: -$5.60 million | Q1 2021: -$6.35 million | Q2 2021: -$4.79 million | Q3 2021: -$6.88 million | Q1 2022: -$7.72 million | Q2 2022: -$5.93 million | Q3 2022: -$5.46 million | Q1 2023: -$5.59 million | Q2 2023: -$6.16 million | Q3 2023: -$6.13 million | Q1 2024: -$5.90 million | Q2 2024: -$5.84 million | Q3 2024: -$4.38 million | Q1 2025: -$1.95 million | Q2 2025: -$1.84 million | Q3 2025: -$1.58 million.
- Over the full 13 years of available data (2013 to 2025), Matinas BioPharma Holdings, Inc.'s Operating Income Loss has declined by 87.5%.
- Historical annual values: Fiscal year 2025: -$6.96 million | Fiscal year 2024: -$24.59 million | Fiscal year 2023: -$23.77 million | Fiscal year 2022: -$24.59 million | Fiscal year 2021: -$24.74 million | Fiscal year 2020: -$24.21 million | Fiscal year 2019: -$18.92 million | Fiscal year 2018: -$14.65 million | Fiscal year 2017: -$16.50 million | Fiscal year 2016: -$8.26 million | Fiscal year 2015: -$9.91 million | Fiscal year 2014: -$10.46 million | Fiscal year 2013: -$3.71 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: